Paulo B.
- Country
- Portugal
- Department
- Oncology
Research Overview
- Phase 1/2 Open‑Label Study of Oral Surzetoclax Monotherapy and Surzetoclax plus Etentamig Combination in Relapsed/Refractory Biomarker‑Selected Multiple Myeloma
- Phase 3 Evaluation of Teclistamab with Lenalidomide versus Lenalidomide Monotherapy in Maintenance Therapy for Newly Diagnosed Multiple Myeloma Post-ASCT
- Phase 3 Open-Label Study of Elranatamab vs. Elotuzumab, Pomalidomide, Dexamethasone, or Carfilzomib in Relapsed/Refractory Multiple Myeloma Post Anti-CD38 Therapy
Data & Insights
Has run more than one trial at 45 of 184 partner sites.
Specializations
Hematologic Oncology
This investigator specializes in treating relapsed and refractory multiple myeloma, focusing on innovative therapeutic approaches for patients who have undergone previous treatments.
- Multiple Myeloma Management
- Advanced Blood Cancer Therapies
- Refractory Disease Treatment
The investigator explores novel treatment modalities for patients with progressive blood cancers who require alternative therapeutic options.
Immunotherapy Research
Their work involves investigating targeted immunotherapy approaches, particularly focusing on antibody-based treatments for blood cancers.
- Monoclonal Antibody Therapy
- Targeted Cancer Treatment
- Immune System Modulation
The investigator examines the effectiveness of various immunotherapeutic agents in treating resistant forms of multiple myeloma.
Treatment Comparison Studies
The investigator evaluates comparative treatment efficacy between different therapeutic regimens in blood cancer management.
- Therapeutic Combinations
- Treatment Response Assessment
- Clinical Outcomes Analysis
Their research encompasses the assessment of various treatment combinations for optimal patient outcomes in resistant disease scenarios.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.